Logo image of AMRX

AMNEAL PHARMACEUTICALS INC (AMRX) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:AMRX - US03168L1052 - Common Stock

11.95 USD
+0.43 (+3.78%)
Last: 11/21/2025, 8:11:58 PM
11.95 USD
0 (0%)
After Hours: 11/21/2025, 8:11:58 PM

AMRX Key Statistics, Chart & Performance

Key Statistics
Market Cap3.75B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Shares314.08M
Float155.90M
52 Week High12.12
52 Week Low6.68
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.75
PE15.93
Fwd PE12.2
Earnings (Next)02-27 2026-02-27/bmo
IPO2009-11-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


AMRX short term performance overview.The bars show the price performance of AMRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

AMRX long term performance overview.The bars show the price performance of AMRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of AMRX is 11.95 USD. In the past month the price increased by 13.27%. In the past year, price increased by 42.43%.

AMNEAL PHARMACEUTICALS INC / AMRX Daily stock chart

AMRX Latest News, Press Relases and Analysis

2 days ago - By: Zacks Investment Research - Mentions: ANIP COLL
10 days ago - By: Amneal Pharmaceuticals LLC
10 days ago - By: Amneal Pharmaceuticals LLC
24 days ago - By: Zacks Investment Research

AMRX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.19 1.00T
JNJ JOHNSON & JOHNSON 19.64 491.06B
MRK MERCK & CO. INC. 11.1 244.18B
PFE PFIZER INC 7.82 142.37B
BMY BRISTOL-MYERS SQUIBB CO 7.05 94.14B
ZTS ZOETIS INC 19.25 54.09B
RPRX ROYALTY PHARMA PLC- CL A 9.47 22.70B
VTRS VIATRIS INC 4.49 12.20B
ELAN ELANCO ANIMAL HEALTH INC 23.18 11.05B
CORT CORCEPT THERAPEUTICS INC 87.83 8.13B
AXSM AXSOME THERAPEUTICS INC N/A 7.46B
BLTE BELITE BIO INC - ADR N/A 4.21B

About AMRX

Company Profile

AMRX logo image Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,100 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Company Info

AMNEAL PHARMACEUTICALS INC

400 Crossing Boulevard, 3rd Floor

Bridgewater NEW JERSEY 08807 US

CEO: Chirag Patel

Employees: 8100

AMRX Company Website

AMRX Investor Relations

Phone: 19089473120

AMNEAL PHARMACEUTICALS INC / AMRX FAQ

What does AMRX do?

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,100 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.


What is the stock price of AMNEAL PHARMACEUTICALS INC today?

The current stock price of AMRX is 11.95 USD. The price increased by 3.78% in the last trading session.


Does AMNEAL PHARMACEUTICALS INC pay dividends?

AMRX does not pay a dividend.


What is the ChartMill technical and fundamental rating of AMRX stock?

AMRX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Which stock exchange lists AMRX stock?

AMRX stock is listed on the Nasdaq exchange.


What do analysts say about AMNEAL PHARMACEUTICALS INC (AMRX) stock?

10 analysts have analysed AMRX and the average price target is 13.6 USD. This implies a price increase of 13.81% is expected in the next year compared to the current price of 11.95.


Should I buy AMRX stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AMRX.


AMRX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to AMRX. When comparing the yearly performance of all stocks, AMRX is one of the better performing stocks in the market, outperforming 91.67% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AMRX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to AMRX. AMRX has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AMRX Financial Highlights

Over the last trailing twelve months AMRX reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 25% compared to the year before.


Industry RankSector Rank
PM (TTM) 0.2%
ROA 0.16%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%6.25%
Sales Q2Q%11.68%
EPS 1Y (TTM)25%
Revenue 1Y (TTM)16.73%

AMRX Forecast & Estimates

10 analysts have analysed AMRX and the average price target is 13.6 USD. This implies a price increase of 13.81% is expected in the next year compared to the current price of 11.95.

For the next year, analysts expect an EPS growth of 42.89% and a revenue growth 8.95% for AMRX


Analysts
Analysts82
Price Target13.6 (13.81%)
EPS Next Y42.89%
Revenue Next Year8.95%

AMRX Ownership

Ownership
Inst Owners41.99%
Ins Owners46.35%
Short Float %3.58%
Short Ratio3.2